title: Lower-dose thalidomide therapy effectively treats cutaneous lupus erythematosus but is limited by neuropathic toxicity.
authors.affiliation: Department of Dermatology and Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USADepartment of Dermatology, University of California Davis, Sacramento, CA, USADepartment of Dermatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USADepartment of Dermatology and Department of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USADepartment of Dermatology and Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
authors.forename: Hillary C
authors.initials: HC
authors.lastname: Frankel
authors.forename: Victoria R
authors.initials: VR
authors.lastname: Sharon
authors.forename: Ruth Ann
authors.initials: RA
authors.lastname: Vleugels
authors.forename: Joseph F
authors.initials: JF
authors.lastname: Merola
authors.forename: Abrar A
authors.initials: AA
authors.lastname: Qureshi
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D008179:Lupus Erythematosus, Discoid / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010292:Paresthesia / Q000139:chemically induced*; D012008:Recurrence; D012189:Retrospective Studies; D013792:Thalidomide / Q000008:administration & dosage* / Q000009:adverse effects; D028761:Withholding Treatment
chemical_list: D007166:Immunosuppressive Agents; D013792:Thalidomide